SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs20417

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 The Role of Functionally Relevant Cyclooxygenase-2 (COX-2) Gene Single Nucleotide Polymorphisms -765G>C and 8473T>C in Lymphocyte Differentiation

Background: - The immune system contains several different types of cells in the blood and other parts of the body. The body can fight infections well with the right balance of these cell types. The wrong balance of cell types may cause diseases, such as allergies or asthma. The COX-2 gene may help decide the balance of cell types that the body makes as part of the immune system. It may also play a role in certain immune system diseases. Researchers want to see how COX-2 affects the cells in the immune system. Objectives: - To study how the COX-2 gene works in the body s immune system. Eligibility: - Individuals 18 years of age and above who are part of the Environmental Polymorphisms Registry. Design: - Participants will have one study visit at the National Institutes of Health. They will collect a urine sample at home on the morning of the study visit. - Participants will have a physical exam and medical history. They will provide a blood sample. They will also give researchers the urine sample they collected that morning. - No treatment will be provided as part of this study.

NCT01678222 Allergic Inflammation Asthma
MeSH: Inflammation

Specifically, the impact of the promoter-region SNP 765G>C (rs20417) and the 3 untranslated region (UTR) SNP 8473T>C (rs5275) on T helper cell (Th) 2, Th9, and Th17 differentiation and function will be examined.

Primary Outcomes

Description: To determine whether 765>C is associated with altered Th2, Th9, and Th17 differentiation in vivo

Measure: To determine whether 765>C is associated with altered Th2, Th9, and Th17 differentiation in vivo

Time: Ongoing

Description: To determine whether 8473T>C is associated with altered Th2, Th9, and Th17 differentiation in vivo

Measure: To determine whether 8473T>C is associated with altered Th2, Th9, and Th17 differentiation in vivo

Time: Ongoing

Secondary Outcomes

Measure: To determine whether 8473T>C is associated with altered Th2, Th9, and Th17 differentiation in vivo

Measure: To determine whether 765G>C is associated with altered prostaglandin and cytokine levels in vivo


HPO Nodes